About Elizabeth Oyekan, PharmD, FCSHP, CPHQ, Vice President, Access Experience Team, PRECISIONvalue

This author has not yet filled in any details.
So far Elizabeth Oyekan, PharmD, FCSHP, CPHQ, Vice President, Access Experience Team, PRECISIONvalue has created 6 blog entries.

Policies and Regulations Impacting IDNs in 2021

Following a tumultuous 2020, IDNs, like many other healthcare systems, are going to be impacted by several elements including an unprecedented number of current and proposed policies. Elizabeth Oyekan discusses 4 policies and regulations that we may see in 2021.

Medicare Advantage Plans: 2020 Focus on Social Determinants of Health

Elizabeth Oyekan examines the increasingly influential role health plans play in the Medicare program, and their shift to focus on social determinants of health. What will new policy and structural changes mean to the plan benefits and offerings in the ever-changing healthcare landscape?

Offensive or Defensive Drug Cost Strategies: Which Will Give Payers and Health Systems the Best Chance to Lower Drug Costs?

When it comes to winning in the effort to reduce rising drug costs, there are new offensive and defensive strategies in play. What works better in pharma? Does a good offense beat a good defense?

Pathway to Success: Proposed CMS Changes to the MSSP ACO Program and Their Implications

After 6 years, CMS is proposing changes to the MSSP, with ACOs set to take on additional risk in an effort to reduce the cost of care to the delivery system and Medicare beneficiaries. Precision’s Elizabeth Oyekan examines the proposed Pathway to Success rule and its central tenet, the adoption of 2-sided risk models.

Pathways to Access: The Evolution of Medical Benefit Management Strategies

Elizabeth Oyekan, Senior Director, Quality and Population Health Solutions, explores the evolution of medical benefit management strategies and helps manufacturers understand where their products fit on clinical pathways—and how those pathways may differ by vendor.